Cargando…

Comment on: “Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”

Detalles Bibliográficos
Autores principales:	Woolcott, John, Cappelleri, Joseph C., Sharma, Puza, Modesto, Irene
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140735/ https://www.ncbi.nlm.nih.gov/pubmed/32173793 http://dx.doi.org/10.1007/s12325-020-01268-3

Ejemplares similares

Response to “Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
por: Moran, Kellyn, et al.
Publicado: (2020)

Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases
por: Moran, Kellyn, et al.
Publicado: (2019)

Persistence With Biologic Therapy and Associated Costs of Patients With Inflammatory Bowel Disease: A German Retrospective Claims Data Analysis
por: Mahlich, Joerg, et al.
Publicado: (2021)

Economic Outcomes Related to Persistence and Dosing of Celecoxib in Patients with Osteoarthritis (OA) Using a Retrospective Claims Database Analysis
por: Johnson, Courtney, et al.
Publicado: (2020)

Adherence and Persistence to Nusinersen for Spinal Muscular Atrophy: A US Claims-Based Analysis
por: Fox, David, et al.
Publicado: (2022)

Experience with Tofacitinib in Patients with Ulcerative Colitis: Data from a United States Claims Database
por: Chiorean, Michael, et al.
Publicado: (2023)

Development of a novel algorithm to determine adherence to chronic pain treatment guidelines using administrative claims
por: Margolis, Jay M, et al.
Publicado: (2017)

Racial or ethnic differences on treatment adherence and persistence among patients with inflammatory bowel diseases initiated with biologic therapies
por: Cai, Qian, et al.
Publicado: (2022)

COVID-19 and adherence to biologic therapies for psoriasis: An analysis of nationwide pharmacy claims data
por: He, Meiqi, et al.
Publicado: (2022)

Persistence and adherence to biologic therapies in juvenile idiopathic arthritis
por: Nieto-González, Juan Carlos, et al.
Publicado: (2021)

Adherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real‐world claims data analysis
por: Sussman, D., et al.
Publicado: (2017)

Adherence to and Persistence with Disease-Modifying Therapies for Multiple Sclerosis Over 24 Months: A Retrospective Claims Analysis
por: Pardo, Gabriel, et al.
Publicado: (2022)

PB2081: TREATMENT PERSISTENCE AND ADHERENCE TO IBRUTINIB IN PATIENTS WITH WALDENSTRÖM MACROGLOBULINEMIA: A GERMAN CLAIMS DATA ANALYSIS
por: Buske, C., et al.
Publicado: (2022)

Persistence and adherence to ocrelizumab compared with other disease-modifying therapies for multiple sclerosis in U.S. commercial claims data
por: Engmann, Natalie J, et al.
Publicado: (2021)

Comments on claimed risk from metastable black holes
por: Giddings, Steven B., et al.
Publicado: (2008)

Adherence and Persistence with First-Line Therapy and Compliance with Glaucoma Guidelines Using Japanese Health Care/Pharmacy Claims Database
por: Shirai, Chikako, et al.
Publicado: (2021)

Comments on Saint’s triad
por: dos Santos, Vitorino Modesto, et al.
Publicado: (2015)

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
por: Carbery, Isabel, et al.
Publicado: (2023)

Tofacitinib Treatment Safety in Moderate to Severe Ulcerative Colitis: Comparison of Observational Population Cohort Data From the IBM MarketScan® Administrative Claims Database With Tofacitinib Trial Data
por: Curtis, Jeffrey R, et al.
Publicado: (2020)

Comparison of adherence and persistence among multiple sclerosis patients treated with disease-modifying therapies: a retrospective administrative claims analysis
por: Halpern, Rachel, et al.
Publicado: (2011)

Treatment patterns, persistence and adherence rates in patients with type 2 diabetes mellitus in Japan: a claims-based cohort study
por: Nishimura, Rimei, et al.
Publicado: (2019)

New biologics and small molecules in inflammatory bowel disease: an update
por: Sabino, João, et al.
Publicado: (2019)

Predictors of adherence to oral anticancer medications: An analysis of 2010-2018 US nationwide claims
por: Vyas, Ami, et al.
Publicado: (2022)

Reduction in the utilization of prednisone or methotrexate in Canadian claims data following initiation of etanercept in pediatric patients with juvenile idiopathic arthritis
por: Khraishi, Majed, et al.
Publicado: (2019)

Adherence and Persistence to Biological Drugs for Psoriasis: Systematic Review with Meta-Analysis
por: Piragine, Eugenia, et al.
Publicado: (2022)

Dubious Claims about Simplicity and Likelihood: Comment on Pinna and Conti (2019)
por: van der Helm, Peter A.
Publicado: (2020)

Medication Adherence and Persistence of Open-Angle Glaucoma Patients in Korea: A Retrospective Study Using National Health Insurance Claims Data
por: Jang, Yunjeong, et al.
Publicado: (2021)

Control of hyperparathyroidism with the intravenous calcimimetic etelcalcetide in dialysis patients adherent and non-adherent to oral calcimimetics
por: Arenas, Maria Dolores, et al.
Publicado: (2020)

Persistence and Adherence to Biologics in Patients with Psoriasis in Taiwan: A New Biologics User Cohort Study
por: Huang, Yu-Huei, et al.
Publicado: (2022)

Adherence to oral second-generation antipsychotic medications in patients with schizophrenia and bipolar disorder: physicians’ perceptions of adherence vs. pharmacy claims
por: Stephenson, J J, et al.
Publicado: (2012)

The Return of the Repressed: The Persistent and Problematic Claims of Long-Forgotten Trauma
por: Otgaar, Henry, et al.
Publicado: (2019)

Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD)
por: Keyloun, Katelyn R., et al.
Publicado: (2017)

Intravenous edaravone treatment in ALS and survival: An exploratory, retrospective, administrative claims analysis
por: Brooks, Benjamin Rix, et al.
Publicado: (2022)

Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data
por: Kuwabara, Hiroyo, et al.
Publicado: (2015)

Direct and indirect predictors of medication adherence by adults with bipolar disorder
por: Cohen, B., et al.
Publicado: (2022)

Comment on persistent hyperinsulinemic hypoglycemia of infancy
por: Prashanth, G. P., et al.
Publicado: (2013)

Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
por: Reinglas, Jason, et al.
Publicado: (2018)

Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease
por: Bilal, Muhammad, et al.
Publicado: (2021)

Role of the combination of biologics and/or small molecules in the treatment of patients with inflammatory bowel disease
por: Balderramo, Domingo
Publicado: (2022)

Adherence and Persistence with DPP-4 Inhibitors Versus Pioglitazone in Type 2 Diabetes Patients with Chronic Kidney Disease: A Retrospective Claims Database Analysis
por: Gor, Deval, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5cqpap883usjs1s1rfm4t7viel